Loading…

Novel and Selective Partial Agonists of 5-HT3 Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines

In continuation of our previous work on piperazinopyrrolothienopyrazine derivatives, three series of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines were prepared and evaluated as 5-HT3 receptor ligands. The chemical modifications performed wi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 1997-06, Vol.40 (12), p.1808-1819
Main Authors: Prunier, Hervé, Rault, Sylvain, Lancelot, Jean-Charles, Robba, Max, Renard, Pierre, Delagrange, Philippe, Pfeiffer, Bruno, Caignard, Daniel-Henri, Misslin, René, Hamon, Michel
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 1819
container_issue 12
container_start_page 1808
container_title Journal of medicinal chemistry
container_volume 40
creator Prunier, Hervé
Rault, Sylvain
Lancelot, Jean-Charles
Robba, Max
Renard, Pierre
Delagrange, Philippe
Pfeiffer, Bruno
Caignard, Daniel-Henri
Misslin, René
Hamon, Michel
description In continuation of our previous work on piperazinopyrrolothienopyrazine derivatives, three series of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines were prepared and evaluated as 5-HT3 receptor ligands. The chemical modifications performed within these new series led to structure−activity relationships regarding both high affinity and selectivity for the 5-HT3 receptors that are in agreement with those established previously for the pyrrolothienopyrazine series. The best compound (8a) obtained in these new series is in the picomolar range of affinity for 5-HT3 receptors with a selectivity higher than 106. Four of the high-affinity 5-HT3 ligands (8a, 15a,b, and 16d) were selected in both the pyridopyrrolopyrazine and the pyrroloquinoxaline series and were characterized in vitro and in vivo as agonists or partial agonists. Compound 8a was also evaluated in the light/dark test where it showed potential anxiolytic-like activity at very low doses per os.
doi_str_mv 10.1021/jm960501o
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_79083615</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79083615</sourcerecordid><originalsourceid>FETCH-LOGICAL-a305t-3d2768ed362eee411bf8cf9d829c6c7475edea84a61a5db1ac0e6a932e17a6133</originalsourceid><addsrcrecordid>eNp1ks-O0zAQxi3EaikLBx4AyQfgRIr_JE5yXHaXXUQFFS1crakzWVzSONhJteUV96XWoVUFB2TJY833-2ak8RDygrMpZ4K_W29KxTLG3SMy4ZlgSVqw9DGZMCZEIpSQT8jTENaMMcmFPCWnJY8nyyfk_rPbYkOhregCGzS93SKdg-8tNPT81rU29IG6mmbJzVLSr2iw650PUyqmdLFr-x8YbPjjf29d426ticarLTQD9Na1o3VuO_Tw27au23lbjbePaAxjEsPbf4lR-zXE9x00e3ms_p8if4PPyEkNTcDnh3hGvn24Wl7cJLMv1x8vzmcJSJb1iaxErgqspBKImHK-qgtTl1UhSqNMnuYZVghFCopDVq04GIYKSimQ5zEn5Rl5s6_b-dgfQ683NhhsGmjRDUHnJSuk4lkEXx7AYbXBSnfebsDv9GH6UX910CHEsdUeWmPDEROqKFU69kv2WPwLvDvK4H9qlcs808v5Qs-KT_klu-T6e-Rf73kwQa_d4Ns4Dc2ZHndFH3dFPgCRjrT4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79083615</pqid></control><display><type>article</type><title>Novel and Selective Partial Agonists of 5-HT3 Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Prunier, Hervé ; Rault, Sylvain ; Lancelot, Jean-Charles ; Robba, Max ; Renard, Pierre ; Delagrange, Philippe ; Pfeiffer, Bruno ; Caignard, Daniel-Henri ; Misslin, René ; Hamon, Michel</creator><creatorcontrib>Prunier, Hervé ; Rault, Sylvain ; Lancelot, Jean-Charles ; Robba, Max ; Renard, Pierre ; Delagrange, Philippe ; Pfeiffer, Bruno ; Caignard, Daniel-Henri ; Misslin, René ; Hamon, Michel</creatorcontrib><description>In continuation of our previous work on piperazinopyrrolothienopyrazine derivatives, three series of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines were prepared and evaluated as 5-HT3 receptor ligands. The chemical modifications performed within these new series led to structure−activity relationships regarding both high affinity and selectivity for the 5-HT3 receptors that are in agreement with those established previously for the pyrrolothienopyrazine series. The best compound (8a) obtained in these new series is in the picomolar range of affinity for 5-HT3 receptors with a selectivity higher than 106. Four of the high-affinity 5-HT3 ligands (8a, 15a,b, and 16d) were selected in both the pyridopyrrolopyrazine and the pyrroloquinoxaline series and were characterized in vitro and in vivo as agonists or partial agonists. Compound 8a was also evaluated in the light/dark test where it showed potential anxiolytic-like activity at very low doses per os.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm960501o</identifier><identifier>PMID: 9191957</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Animals ; Anti-Anxiety Agents - chemical synthesis ; Anti-Anxiety Agents - metabolism ; Anti-Anxiety Agents - therapeutic use ; Anxiety - drug therapy ; Anxiety - etiology ; Biological and medical sciences ; Cattle ; Cell Membrane - metabolism ; Corpus Striatum - metabolism ; Darkness ; Frontal Lobe - metabolism ; Guanidine ; Guanidines - metabolism ; Hippocampus - metabolism ; Light ; Male ; Medical sciences ; Molecular Structure ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Pharmacology. Drug treatments ; Pyrazines - chemical synthesis ; Pyrazines - metabolism ; Pyrazines - therapeutic use ; Pyridines - chemical synthesis ; Pyridines - metabolism ; Pyridines - therapeutic use ; Rats ; Receptors, Serotonin - metabolism ; Receptors, Serotonin, 5-HT3 ; Serotonin Receptor Agonists - chemical synthesis ; Serotonin Receptor Agonists - metabolism ; Serotonin Receptor Agonists - therapeutic use ; Serotoninergic system ; Structure-Activity Relationship ; Swine</subject><ispartof>Journal of medicinal chemistry, 1997-06, Vol.40 (12), p.1808-1819</ispartof><rights>Copyright © 1997 American Chemical Society</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2689643$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9191957$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Prunier, Hervé</creatorcontrib><creatorcontrib>Rault, Sylvain</creatorcontrib><creatorcontrib>Lancelot, Jean-Charles</creatorcontrib><creatorcontrib>Robba, Max</creatorcontrib><creatorcontrib>Renard, Pierre</creatorcontrib><creatorcontrib>Delagrange, Philippe</creatorcontrib><creatorcontrib>Pfeiffer, Bruno</creatorcontrib><creatorcontrib>Caignard, Daniel-Henri</creatorcontrib><creatorcontrib>Misslin, René</creatorcontrib><creatorcontrib>Hamon, Michel</creatorcontrib><title>Novel and Selective Partial Agonists of 5-HT3 Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>In continuation of our previous work on piperazinopyrrolothienopyrazine derivatives, three series of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines were prepared and evaluated as 5-HT3 receptor ligands. The chemical modifications performed within these new series led to structure−activity relationships regarding both high affinity and selectivity for the 5-HT3 receptors that are in agreement with those established previously for the pyrrolothienopyrazine series. The best compound (8a) obtained in these new series is in the picomolar range of affinity for 5-HT3 receptors with a selectivity higher than 106. Four of the high-affinity 5-HT3 ligands (8a, 15a,b, and 16d) were selected in both the pyridopyrrolopyrazine and the pyrroloquinoxaline series and were characterized in vitro and in vivo as agonists or partial agonists. Compound 8a was also evaluated in the light/dark test where it showed potential anxiolytic-like activity at very low doses per os.</description><subject>Animals</subject><subject>Anti-Anxiety Agents - chemical synthesis</subject><subject>Anti-Anxiety Agents - metabolism</subject><subject>Anti-Anxiety Agents - therapeutic use</subject><subject>Anxiety - drug therapy</subject><subject>Anxiety - etiology</subject><subject>Biological and medical sciences</subject><subject>Cattle</subject><subject>Cell Membrane - metabolism</subject><subject>Corpus Striatum - metabolism</subject><subject>Darkness</subject><subject>Frontal Lobe - metabolism</subject><subject>Guanidine</subject><subject>Guanidines - metabolism</subject><subject>Hippocampus - metabolism</subject><subject>Light</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Molecular Structure</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrazines - chemical synthesis</subject><subject>Pyrazines - metabolism</subject><subject>Pyrazines - therapeutic use</subject><subject>Pyridines - chemical synthesis</subject><subject>Pyridines - metabolism</subject><subject>Pyridines - therapeutic use</subject><subject>Rats</subject><subject>Receptors, Serotonin - metabolism</subject><subject>Receptors, Serotonin, 5-HT3</subject><subject>Serotonin Receptor Agonists - chemical synthesis</subject><subject>Serotonin Receptor Agonists - metabolism</subject><subject>Serotonin Receptor Agonists - therapeutic use</subject><subject>Serotoninergic system</subject><subject>Structure-Activity Relationship</subject><subject>Swine</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNp1ks-O0zAQxi3EaikLBx4AyQfgRIr_JE5yXHaXXUQFFS1crakzWVzSONhJteUV96XWoVUFB2TJY833-2ak8RDygrMpZ4K_W29KxTLG3SMy4ZlgSVqw9DGZMCZEIpSQT8jTENaMMcmFPCWnJY8nyyfk_rPbYkOhregCGzS93SKdg-8tNPT81rU29IG6mmbJzVLSr2iw650PUyqmdLFr-x8YbPjjf29d426ticarLTQD9Na1o3VuO_Tw27au23lbjbePaAxjEsPbf4lR-zXE9x00e3ms_p8if4PPyEkNTcDnh3hGvn24Wl7cJLMv1x8vzmcJSJb1iaxErgqspBKImHK-qgtTl1UhSqNMnuYZVghFCopDVq04GIYKSimQ5zEn5Rl5s6_b-dgfQ683NhhsGmjRDUHnJSuk4lkEXx7AYbXBSnfebsDv9GH6UX910CHEsdUeWmPDEROqKFU69kv2WPwLvDvK4H9qlcs808v5Qs-KT_klu-T6e-Rf73kwQa_d4Ns4Dc2ZHndFH3dFPgCRjrT4</recordid><startdate>19970606</startdate><enddate>19970606</enddate><creator>Prunier, Hervé</creator><creator>Rault, Sylvain</creator><creator>Lancelot, Jean-Charles</creator><creator>Robba, Max</creator><creator>Renard, Pierre</creator><creator>Delagrange, Philippe</creator><creator>Pfeiffer, Bruno</creator><creator>Caignard, Daniel-Henri</creator><creator>Misslin, René</creator><creator>Hamon, Michel</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19970606</creationdate><title>Novel and Selective Partial Agonists of 5-HT3 Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines</title><author>Prunier, Hervé ; Rault, Sylvain ; Lancelot, Jean-Charles ; Robba, Max ; Renard, Pierre ; Delagrange, Philippe ; Pfeiffer, Bruno ; Caignard, Daniel-Henri ; Misslin, René ; Hamon, Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a305t-3d2768ed362eee411bf8cf9d829c6c7475edea84a61a5db1ac0e6a932e17a6133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Animals</topic><topic>Anti-Anxiety Agents - chemical synthesis</topic><topic>Anti-Anxiety Agents - metabolism</topic><topic>Anti-Anxiety Agents - therapeutic use</topic><topic>Anxiety - drug therapy</topic><topic>Anxiety - etiology</topic><topic>Biological and medical sciences</topic><topic>Cattle</topic><topic>Cell Membrane - metabolism</topic><topic>Corpus Striatum - metabolism</topic><topic>Darkness</topic><topic>Frontal Lobe - metabolism</topic><topic>Guanidine</topic><topic>Guanidines - metabolism</topic><topic>Hippocampus - metabolism</topic><topic>Light</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Molecular Structure</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrazines - chemical synthesis</topic><topic>Pyrazines - metabolism</topic><topic>Pyrazines - therapeutic use</topic><topic>Pyridines - chemical synthesis</topic><topic>Pyridines - metabolism</topic><topic>Pyridines - therapeutic use</topic><topic>Rats</topic><topic>Receptors, Serotonin - metabolism</topic><topic>Receptors, Serotonin, 5-HT3</topic><topic>Serotonin Receptor Agonists - chemical synthesis</topic><topic>Serotonin Receptor Agonists - metabolism</topic><topic>Serotonin Receptor Agonists - therapeutic use</topic><topic>Serotoninergic system</topic><topic>Structure-Activity Relationship</topic><topic>Swine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Prunier, Hervé</creatorcontrib><creatorcontrib>Rault, Sylvain</creatorcontrib><creatorcontrib>Lancelot, Jean-Charles</creatorcontrib><creatorcontrib>Robba, Max</creatorcontrib><creatorcontrib>Renard, Pierre</creatorcontrib><creatorcontrib>Delagrange, Philippe</creatorcontrib><creatorcontrib>Pfeiffer, Bruno</creatorcontrib><creatorcontrib>Caignard, Daniel-Henri</creatorcontrib><creatorcontrib>Misslin, René</creatorcontrib><creatorcontrib>Hamon, Michel</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prunier, Hervé</au><au>Rault, Sylvain</au><au>Lancelot, Jean-Charles</au><au>Robba, Max</au><au>Renard, Pierre</au><au>Delagrange, Philippe</au><au>Pfeiffer, Bruno</au><au>Caignard, Daniel-Henri</au><au>Misslin, René</au><au>Hamon, Michel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel and Selective Partial Agonists of 5-HT3 Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1997-06-06</date><risdate>1997</risdate><volume>40</volume><issue>12</issue><spage>1808</spage><epage>1819</epage><pages>1808-1819</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>In continuation of our previous work on piperazinopyrrolothienopyrazine derivatives, three series of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines were prepared and evaluated as 5-HT3 receptor ligands. The chemical modifications performed within these new series led to structure−activity relationships regarding both high affinity and selectivity for the 5-HT3 receptors that are in agreement with those established previously for the pyrrolothienopyrazine series. The best compound (8a) obtained in these new series is in the picomolar range of affinity for 5-HT3 receptors with a selectivity higher than 106. Four of the high-affinity 5-HT3 ligands (8a, 15a,b, and 16d) were selected in both the pyridopyrrolopyrazine and the pyrroloquinoxaline series and were characterized in vitro and in vivo as agonists or partial agonists. Compound 8a was also evaluated in the light/dark test where it showed potential anxiolytic-like activity at very low doses per os.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>9191957</pmid><doi>10.1021/jm960501o</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 1997-06, Vol.40 (12), p.1808-1819
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_79083615
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
subjects Animals
Anti-Anxiety Agents - chemical synthesis
Anti-Anxiety Agents - metabolism
Anti-Anxiety Agents - therapeutic use
Anxiety - drug therapy
Anxiety - etiology
Biological and medical sciences
Cattle
Cell Membrane - metabolism
Corpus Striatum - metabolism
Darkness
Frontal Lobe - metabolism
Guanidine
Guanidines - metabolism
Hippocampus - metabolism
Light
Male
Medical sciences
Molecular Structure
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Pharmacology. Drug treatments
Pyrazines - chemical synthesis
Pyrazines - metabolism
Pyrazines - therapeutic use
Pyridines - chemical synthesis
Pyridines - metabolism
Pyridines - therapeutic use
Rats
Receptors, Serotonin - metabolism
Receptors, Serotonin, 5-HT3
Serotonin Receptor Agonists - chemical synthesis
Serotonin Receptor Agonists - metabolism
Serotonin Receptor Agonists - therapeutic use
Serotoninergic system
Structure-Activity Relationship
Swine
title Novel and Selective Partial Agonists of 5-HT3 Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T06%3A53%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20and%20Selective%20Partial%20Agonists%20of%205-HT3%20Receptors.%202.%20Synthesis%20and%20Biological%20Evaluation%20of%20Piperazinopyridopyrrolopyrazines,%20Piperazinopyrroloquinoxalines,%20and%20Piperazinopyridopyrroloquinoxalines&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Prunier,%20Herv%C3%A9&rft.date=1997-06-06&rft.volume=40&rft.issue=12&rft.spage=1808&rft.epage=1819&rft.pages=1808-1819&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm960501o&rft_dat=%3Cproquest_pubme%3E79083615%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a305t-3d2768ed362eee411bf8cf9d829c6c7475edea84a61a5db1ac0e6a932e17a6133%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=79083615&rft_id=info:pmid/9191957&rfr_iscdi=true